First Thing, Daily Maverick's flagship newsletter

Join the 230 000 South Africans who read First Thing newsletter.

We'd like our readers to start paying for Daily Maverick

More specifically, we'd like those who can afford to pay to start paying. What it comes down to is whether or not you value Daily Maverick. Think of us in terms of your daily cappuccino from your favourite coffee shop. It costs around R35. That’s R1,050 per month on frothy milk. Don’t get us wrong, we’re almost exclusively fuelled by coffee. BUT maybe R200 of that R1,050 could go to the journalism that’s fighting for the country?

We don’t dictate how much we’d like our readers to contribute. After all, how much you value our work is subjective (and frankly, every amount helps). At R200, you get it back in Uber Eats and ride vouchers every month, but that’s just a suggestion. A little less than a week’s worth of cappuccinos.

We can't survive on hope and our own determination. Our country is going to be considerably worse off if we don’t have a strong, sustainable news media. If you’re rejigging your budgets, and it comes to choosing between frothy milk and Daily Maverick, we hope you might reconsider that cappuccino.

We need your help. And we’re not ashamed to ask for it.

Our mission is to Defend Truth. Join Maverick Insider.

Support Daily Maverick→
Payment options

Aspen Pharmacare to Deliver J&J Vaccines in Next Three...

Newsdeck

Newsdeck

Aspen Pharmacare to Deliver J&J Vaccines in Next Three Months

A shipment of the Johnson & Johnson Janssen Covid-19 vaccine arrives at Northwell Health South Shore University Hospital in Bay Shore, New York.
By Bloomberg
15 Mar 2021 0

(Bloomberg) --Aspen Pharmacare Holdings Ltd. will supply the Covid-19 vaccine developed by Johnson & Johnson within the next three months, putting Africa’s biggest drugmaker “right up front of producing this vaccine globally,” Chief Executive Officer Stephen Saad said.

By Janice Kew
Mar 12, 2021, 3:58 PM
Word Count: 256

Since agreeing in November to produce as many as 300 million doses a year at its plant in Port Elizabeth, South Africa, Aspen has adopted the technology needed for production, Saad said in an interview Friday. The company has sufficient capacity to more than double that output if needed, he said.

Next, Aspen needs to produce three batches identical to the end product. Once that target is met, Aspen can apply for registration and then sell its supply of the J&J vaccine, which received clearance in the European Union this week after an emergency use authorization in the U.S.

Aspen’s heft could help a continent with otherwise limited vaccine manufacturing capacity and alleviate some concerns that poorer nations will be left without supplies due to the huge demand from richer countries.

South Africa is “in a great position as a country around procurement of vaccines because of what Aspen can offer,” Saad said.

The company, which on Thursday said it plans to resume paying dividends after a two-year break enforced by debt levels, is now in a position to make acquisitions.

Any purchases would be “additive rather than transformative,” Saad said. Aspen would look at countries or business areas in which it already operates, including buying sterile products, which are mostly used in hospitals, or a vaccine, he said.

© 2021 Bloomberg L.P.
Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]
Gallery

Please peer review 3 community comments before your comment can be posted